Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker

BenzingaAug 28 04:21 ET

Eli Lilly and Co's Alzheimer's drug, Donanemab, may be rejected by the United Kingdom's healthcare regulatory institutions.

After the regulatory institutions in the United Kingdom refused to approve Leqembi, the Alzheimer's disease drug owned by Baijian, for use in the National Health Service (NHS), there have been reports that Donanemab, another Alzheimer's disease drug owned by Eli Lilly and Co, will face the same fate.

Zhitong FinanceAug 25 22:15 ET

Eli Lilly Alzheimer's Drug Set to Face Same Fate as Biogen's in U.K.: Report

Seeking AlphaAug 24 13:16 ET

Biopharmaceuticals Global Business Report 2024 With Focus on 200+ Select Players Including Abbott, Amgen, Biogen, Eli Lilly and Co, F. Hoffmann-La Roche, J&J, Merck, Novo Nordisk, Pfizer, Sanofi

Yahoo FinanceAug 23 07:20 ET

Eisai and Biogen's Alzheimer's Drug Leqembi Receives MHRA Approval in Great Britain

MT NewswiresAug 22 22:11 ET

Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement

BenzingaAug 22 13:45 ET